GO:1901753 leukotriene A4 biosynthetic process

Leukotriene A4 (LTA4) is a central, highly reactive intermediate in the biosynthesis of leukotrienes, a family of lipid mediators derived from arachidonic acid. The Gene Ontology term GO:1901753, leukotriene A4 biosynthetic process, captures the set of chemical reactions and pathways that result in the formation of LTA4. This process is initiated when arachidonic acid is liberated from membrane phospholipids and presented to 5-lipoxygenase (ALOX5), which, together with 5-lipoxygenase-activating protein (ALOX5AP, also known as FLAP), catalyzes the conversion of arachidonic acid to LTA4 via the intermediate 5-hydroperoxyeicosatetraenoic acid (5-HPETE). Because LTA4 is unstable and serves as the substrate for multiple downstream enzymes, its biosynthesis represents a key regulatory node in inflammatory and immune signaling. Researchers study GO:1901753 to understand how lipid mediators are produced in health and disease. The enzymes involved in LTA4 biosynthesis are expressed in various cell types, including neutrophils, mast cells, macrophages, and platelets, and their activity is tightly regulated by calcium, ATP, and membrane interactions. The term is also relevant to transcellular biosynthesis, where LTA4 produced by one cell can be exported and converted by another cell, thereby integrating signals across cell populations. From a disease perspective, excessive or dysregulated LTA4 biosynthesis has been linked to chronic inflammatory conditions such as asthma, arthritis, and inflammatory bowel disease, as well as to cancer progression. Consequently, the enzymes of this pathway, particularly ALOX5, ALOX5AP, and LTA4H, are considered attractive targets for therapeutic intervention. Understanding the precise molecular steps and regulatory mechanisms of LTA4 biosynthesis is therefore essential for developing new treatments and for interpreting experimental data in the context of eicosanoid biology.

GO:1901753 (leukotriene A4 biosynthetic process) is defined as the chemical reactions and pathways resulting in the formation of leukotriene A4 (LTA4). In practice, this term encompasses the enzymatic steps that convert arachidonic acid into the unstable epoxide LTA4, primarily through the action of 5-lipoxygenase (ALOX5) in concert with its activating protein (ALOX5AP/FLAP). The term is a biological process and includes the synthesis, formation, and anabolism of LTA4, as reflected by its synonyms such as LTA4 biosynthesis and leukotriene A4 synthesis.

GO:1901753 is important because LTA4 is the pivotal intermediate that links the initial lipoxygenase step to the diverse family of leukotrienes, which are potent lipid mediators of inflammation, immunity, and cancer. The biosynthesis of LTA4 is tightly regulated and represents a rate-limiting point in leukotriene production; therefore, understanding this process provides insight into how inflammatory responses are initiated and sustained. Moreover, because LTA4 can be converted to either LTB4 (a neutrophil chemoattractant) or cysteinyl leukotrienes (bronchoconstrictors), the regulation of LTA4 formation directly influences the balance of downstream mediators. This makes the pathway a prime target for anti-inflammatory drug discovery and a focus for cancer chemoprevention research.

The following genes and proteins are directly involved in or closely associated with the leukotriene A4 biosynthetic process (GO:1901753), based on published literature.

The leukotriene A4 biosynthetic process is regulated at multiple levels. Acute regulation involves calcium-dependent translocation of ALOX5 to the nuclear envelope, where it interacts with FLAP and other enzymes. ATP is required for the catalytic cycle, and phosphorylation by kinases such as MAPKAPK2 and ERK modulates ALOX5 activity. Transcriptional regulation of ALOX5, ALOX5AP, and LTA4H occurs in response to inflammatory cytokines such as IL-4 and TNF, which can upregulate pathway components. Additionally, substrate availability is controlled by phospholipase A2 enzymes that release arachidonic acid from membranes. Transcellular biosynthesis provides a further layer of regulation by allowing LTA4 to be transferred between cells, thereby integrating local and systemic inflammatory signals.

LTA4 biosynthesis is a central step in the production of leukotrienes, which are potent mediators of inflammation and bronchoconstriction. Elevated levels of leukotrienes are found in the airways of asthmatic patients, and genetic variants in ALOX5 and ALOX5AP have been associated with asthma susceptibility. Inhibitors of 5-lipoxygenase and FLAP reduce leukotriene production and are used experimentally to probe the role of this pathway in allergic inflammation. The transcellular biosynthesis of LTA4 further amplifies inflammation by allowing leukocytes to cooperate with structural cells in the lung.

Chronic inflammation is a risk factor for many cancers, and leukotrienes derived from LTA4 have been implicated in tumor progression. LTA4 hydrolase (LTA4H), which converts LTA4 to LTB4, is considered a target for cancer chemoprevention and chemotherapy. Studies suggest that LTB4 promotes tumor cell proliferation and survival, while inhibition of LTA4H or 5-lipoxygenase can reduce tumor growth in preclinical models. Thus, the LTA4 biosynthetic process is a potential node for therapeutic intervention in inflammation-associated cancers.

Leukotrienes contribute to vascular inflammation, atherosclerosis, and cardiovascular disease. The LTA4 biosynthetic pathway, through the production of LTB4 and cysteinyl leukotrienes, promotes leukocyte recruitment and endothelial dysfunction. Genetic polymorphisms in ALOX5AP have been linked to increased risk of myocardial infarction and stroke. Additionally, LTA4 biosynthesis is implicated in inflammatory bowel disease and arthritis, where leukotriene levels correlate with disease activity.

The biosynthesis of LTA4 can be measured using enzyme activity assays that monitor the conversion of arachidonic acid to 5-HPETE and LTA4, often coupled with high-performance liquid chromatography (HPLC) or mass spectrometry. Lipidomics approaches, such as LC-MS/MS, allow quantification of LTA4 and its downstream metabolites (LTB4, LTC4) in cell culture media or tissue samples. These methods are essential for validating the impact of genetic perturbations on the pathway.

Genome-wide CRISPR knockout or activation screens can identify genes that regulate LTA4 biosynthesis. For example, a screen using a leukotriene-responsive reporter or direct lipid measurement can uncover novel regulators of ALOX5 or FLAP activity. Such screens are powerful for discovering previously unknown components of the pathway and for validating drug targets.

RNA sequencing (RNA-seq) can reveal changes in the expression of ALOX5, ALOX5AP, LTA4H, and other pathway genes under different conditions. Proteomics, including phosphoproteomics, can identify post-translational modifications of ALOX5 and interacting proteins that regulate LTA4 biosynthesis. These approaches provide a systems-level view of pathway regulation.

Fluorescence microscopy and subcellular fractionation are used to study the translocation of ALOX5 to the nuclear envelope and its co-localization with FLAP and other enzymes. Live-cell imaging with tagged proteins can visualize the dynamic assembly of the LTA4 biosynthetic complex in real time.

Researchers studying leukotriene A4 biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in LTA4 production, how specific mutations affect enzyme function, or whether overexpression alters downstream leukotriene signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.

GO:1901753 (leukotriene A4 biosynthetic process) is a fundamental biological process that governs the production of a key lipid mediator, LTA4, which sits at the crossroads of inflammatory and immune signaling. The pathway is driven by the coordinated action of ALOX5, FLAP, and downstream enzymes, and its dysregulation contributes to asthma, cardiovascular disease, and cancer. Understanding the molecular details and regulation of LTA4 biosynthesis offers opportunities for therapeutic intervention and biomarker discovery. Researchers can leverage CRISPR-based tools to create knockout, point-mutation, knock-in, and overexpression models to study this pathway with precision. EDITGENE provides end-to-end support for such studies, from cell model generation to library screening and bioinformatics, helping to accelerate discoveries in eicosanoid biology and inflammation research.